Xiao-Ling Li

China Medical University - Medical Oncology Department of Thoracic Cancer

Shenyang

China

SCHOLARLY PAPERS

1

DOWNLOADS

38

SSRN CITATIONS

1

CROSSREF CITATIONS

0

Scholarly Papers (1)

1.

Bevacizumab Plus Erlotinib in Chinese Patients with Untreated, EGFR-Mutated, Advanced NSCLC (ARTEMIS-CTONG1509): A Multicenter Phase 3 Study

Number of pages: 56 Posted: 19 Dec 2020
Guangdong Academy of Medical Sciences - Guangdong Lung Cancer Institute, Jilin Provincial Tumor Hospital - Department of Thoracic Oncology, China Medical University - Department of Medical Oncology, Harbin Medical University - Cancer Hospital, Jilin University (JLU) - The Cancer Center, Central South University - Department of Medical Oncology, Nanjing Military General Hospital - Respiratory Medicine, China Medical University - Medical Oncology Department of Thoracic Cancer, Shanghai Jiao Tong University (SJTU) - Medical Oncology, Zhejiang University - Respiratory Medicine, Henan Cancer Hospital - Respiratory Medicine, Huazhong University of Science and Technology (Formerly Tongi Medical University) - Medical Oncology, Fujian Cancer Hospital - Medical Oncology, Nanjing Medical University - Department of Oncology and Guangdong Academy of Medical Sciences - Guangdong Lung Cancer Institute
Downloads 38 (786,071)
Citation 4

Abstract:

Loading...

bevacizumab, EGFR mutation, epidermal growth factor inhibitor, erlotinib, non-small-cell lung cancer, vascular endothelial growth factor inhibitor